肿瘤患者使用重组人粒细胞集落刺激因子DUE标准的建立与应用

摘要

目的：为肿瘤患者合理使用重组人粒细胞集落刺激因子（rhG-CSF）提供参考。方法：参考国内外rhG-CSF临床应用指南，结合专家咨询法，建立肿瘤患者使用rhG-CSF的药物利用评估（DUE）标准；设计患者使用rhG-CSF调查表，评价某“三甲”医院220份使用了rhG-CSF的病历资料。结果：肿瘤患者rhG-CSF的DUE标准包括用药指征、用药过程和用药结果三部分，共14条内容。运用建立的DUE标准对220份病历进行回顾性评估，结果发现该院rhG-CSF应用在符合用药指征、无禁忌证、每周至少监测2次血常规和药物相互作用方面达到了标准预期目标值，但尚存在一些不合理情况。结论：建立的肿瘤患者使用rhG-CSF DUE标准具有评价内容明确、针对性强、实用性好等优点，可为医师和临床药师开展工作提供参考。%OBJECTIVE:To provide reference for rational use of recombinant human granulocyte-colony stimulating factor (rhG-CSF) in cancer patients. METHODS:Referring to the expert advice and guideline of clinical application of rhG-CSF at home and abroad,DUE criteria on rhG-CSF for cancer patients was established;questionnaire was designed,and the medical re-cords of rhG-CSF in a third grade class A hospital was evaluated. RESULTS:The DUE criterion on rhG-CSF for cancer patients included 3 parts,such as drug indications,the course of medication and medication results,14 items in total. Through the imple-mentation of DUE,retrospective evaluation of 220 medical records showed that the application of rhG-CSF was up to the stan-dard in respects of drug indications,no contraindication,routine blood test and drug interaction monitoring at least twice every week,there still was irrational phenomenon. CONCLUSIONS:The established DUE criterion on rhG-CSF for cancer patients is with the characteristics of definite content,target and paracticabilitg,which can provide reference for the work development of clinical pharmacists.